GlassScriptPhysician profile
Isaac E Silverman
NPI 1326058108
$23,631.75
in general payments reported to CMS, 2019-2025
48 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,898 · 2021: $219 · 2022: $98.55 · 2023: $441 · 2024: $1,018 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20,037.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $651.08 | 2019-2025 | |
| Ucb, INC. | $321.43 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Mdd US Operations, LLC | $321.09 | 2024-2025 | Gocovri |
| Amgen INC. | $167.54 | 2019-2025 | Uplizna |
| Portola Pharmaceuticals, LLC | $130.49 | 2020 | |
| Acadia Pharmaceuticals INC | $117.28 | 2019-2023 | Nuplazid |
| Ge Healthcare | $114.42 | 2021-2025 | |
| Abbvie INC. | $114.24 | 2019-2024 | Qulipta |
| Genzyme Corporation | $109.76 | 2019-2025 | |
| Genentech USA, INC. | $107.91 | 2020-2024 | Ocrevus Zunovo, Ocrevus |
| Grifols USA, LLC | $98.99 | 2019-2024 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $93.80 | 2024-2025 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $72.87 | 2019-2020 | |
| Allergan, INC. | $70.67 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.